EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR
EPA:ALVAL (6/18/2025, 7:00:00 PM)
0.878
0 (-0.23%)
The current stock price of ALVAL.PA is 0.878 EUR. In the past month the price decreased by -19.74%. In the past year, price decreased by -37.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 18.69 | 293.65B | ||
4AB.DE | ABBVIE INC | 18.27 | 286.51B | ||
AMG.DE | AMGEN INC | 14.05 | 135.61B | ||
GIS.DE | GILEAD SCIENCES INC | 14.05 | 116.93B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 99.95B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.98 | 49.56B | ||
ARGX.BR | ARGENX SE | 102.34 | 28.87B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.85B | ||
IDP.DE | BIOGEN INC | 8.09 | 16.21B | ||
1EXEL.MI | EXELIXIS INC | 18.93 | 9.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.71B | ||
0QF.DE | MODERNA INC | N/A | 8.64B |
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
VALBIOTIS SA
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 52
The current stock price of ALVAL.PA is 0.878 EUR. The price decreased by -0.23% in the last trading session.
The exchange symbol of VALBIOTIS SA is ALVAL and it is listed on the Euronext Paris - Matif exchange.
ALVAL.PA stock is listed on the Euronext Paris - Matif exchange.
11 analysts have analysed ALVAL.PA and the average price target is 3.43 EUR. This implies a price increase of 291.12% is expected in the next year compared to the current price of 0.878. Check the VALBIOTIS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VALBIOTIS SA (ALVAL.PA) has a market capitalization of 13.97M EUR. This makes ALVAL.PA a Nano Cap stock.
VALBIOTIS SA (ALVAL.PA) currently has 52 employees.
VALBIOTIS SA (ALVAL.PA) has a resistance level at 0.97. Check the full technical report for a detailed analysis of ALVAL.PA support and resistance levels.
The Revenue of VALBIOTIS SA (ALVAL.PA) is expected to decline by -96.57% in the next year. Check the estimates tab for more information on the ALVAL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVAL.PA does not pay a dividend.
VALBIOTIS SA (ALVAL.PA) will report earnings on 2025-10-27.
VALBIOTIS SA (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).
ChartMill assigns a fundamental rating of 3 / 10 to ALVAL.PA. ALVAL.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 22.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.58% | ||
ROE | -53.12% | ||
Debt/Equity | 0.24 |
ChartMill assigns a Buy % Consensus number of 85% to ALVAL.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -4.38% and a revenue growth -96.57% for ALVAL.PA